Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Tide Has Changed, but That Doesn’t Erase Concerns: FPMAJ Drug Pricing Chief
June 12, 2023
-
BUSINESS FDA Advisors Back Full Approval of Eisai’s Alzheimer’s Med
June 12, 2023
-
BUSINESS AstraZeneca Crowned in Foreign Pharma Ranking for 2nd Year Straight, Followed by MSD
June 9, 2023
-
REGULATORY Honebuto Social Security Debate Culminates with LDP Push for Nixing Budget Cap
June 9, 2023
-
REGULATORY Sumitomo to Urge Switch from Noritren over Carcinogen Risks, but Continues Shipments
June 8, 2023
-
REGULATORY Draft Honebuto Paper Unveiled, Cabinet OK Expected in Mid-June
June 8, 2023
-
REGULATORY Draft Honebuto Paper Calls for Further Drug Pricing Measures to Reward Innovation
June 7, 2023
-
ORGANIZATION Industry’s Concerns Beginning to Sink in among Policymakers: JPMA Committee Chair
June 7, 2023
-
BUSINESS Japan Firms Joining Fray in siRNA Drug Development; Takeda Could File as Early as FY2025
June 6, 2023
-
REGULATORY Expert Panel to Propose Setting Up Requirements for Generic Entry to Ensure Stable Supplies; Draft Report Due Out June 6
June 5, 2023
-
REGULATORY Expert Panel Pushes Fresh Evaluation Approach for New Drug Pricing, Rethink of Spillovers: Draft Report
June 5, 2023
-
BUSINESS Shionogi Shoots for Doubling Revenue to 800 Billion Yen by FY2030
June 2, 2023
-
BUSINESS Pharma Companies in Japan Raising Retirement Age, Extending Rehiring: Jiho Poll
June 1, 2023
-
BUSINESS AbbVie Aims to Double Japan Sales to 200 Billion Yen by 2030: Local Chief
May 31, 2023
-
REGULATORY Japan to Launch New Forum to Spur Secondary Use of Medical Data in Drug Discovery
May 30, 2023
-
REGULATORY MOF Panel Flags Japan’s High Drug Cost per Capita, Stays Pat on Cost-Effectiveness-Based Reimbursement, Copay Review
May 30, 2023
-
BUSINESS Jeremy Grossas to Head Up Merck Biopharma Japan
May 30, 2023
-
REGULATORY PM Advisors Make Irregular Call for Properly Rewarding Innovation to Boost Japan’s Drug Discovery Capabilities
May 29, 2023
-
REGULATORY Gene Therapy Luxturna Now in Line for Approval in June
May 29, 2023
-
BUSINESS Pfizer Japan Files RSV Vaccine for 60 Years of Age and Older
May 29, 2023
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…